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Abstract
The need for faster diagnosis, more accurate prognostic assessment and treatment decisions in various diseases has lead to the investigations of new 
biomarkers. The hope is that this new biomarkers will enable early decision making in clinical practice. Arginine vasopressin (AVP) is one of the main 
hormones of the hypothalamic-pituitary-adrenal axis. Its main stimulus for secretion is hyperosmolarity, but AVP system is also stimulated by ex-
posure of the body to endogenous stress. Reliable measurement of AVP concentration is diffi  cult because it is subject to preanalytical and analytical 
errors. It is therefore not used in clinical practice. Copeptin, a 39-aminoacid glycopeptide, is a C-terminal part of the precursor pre-provasopressin 
(pre-proAVP). Activation of AVP system stimulates copeptin secretion into the circulation from the posterior pituitary gland in equimolar amounts 
with AVP. Therefore, copeptin directly refl ects AVP concentration and can be used as surrogate biomarker of AVP secretion. Even mild to moderate 
stress situations contribute to release of copeptin. These reasons have lead to a handful of research on copeptin in various diseases. This review sum-
marizes the current achievements in the research of copeptin as a diagnostic and prognostic marker and also discusses its association in diff erent 
disease processes.
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Review
Introduction
Copeptin, a 39-aminoacid glycopeptide is a C-ter-
minal part of pre-provasopressin (pre-proAVP). 
Pre-proAVP is a precursor protein which consists 
of a signal peptide, arginine vasopressin (AVP), 
neurophysin II and copeptin (1-3). These compo-
nents are separated during axon transport from 
the cell body to the axon terminals in the posterior 
pituitary gland (3). On the path from the hypotha-
lamus to the pituitary gland, copeptin and neuro-
physin II act as carrier proteins of AVP. Copeptin is 
stored in the neurohypophyseal vesicles together 
with AVP and neurophysin II until they are secret-
ed (4). Schematic presentation of copeptin genera-
tion and maturation is shown in Figure 1. Copeptin 
also has a very important role in the proteolysis of 
pre-proAVP, but its main role in the circulation is 
still unknown (3,6). Slow degradation of copeptin 
in humans hints that this peptide may not have 
any signifi cant function in the circulation (6). 
Copeptin is cosynthesized with AVP and is found 
in equimolar amounts with AVP in the circulation 
of healthy and critically ill subjects (7,8). Thus 
copeptin mirrors AVP concentration and can be 
used as a replacement biomarker of AVP release 
(6,7).
For certain diseases, diagnosis and prognosis can 
still be very demanding and time-consuming. This 
is why new biomarkers are needed to aid clinicians 
in making faster treatment decisions and more ac-
curate prognostic assessment. To be of practical 
value, a new biomarker needs to provide quantita-
tive information that is both reliable and reproduc-
ible. Moreover, the measurement of a biomarker 
should be easy, rapid and inexpensive to perform. 
Therefore, copeptin has been proposed as a prog-
nostic marker in diff erent illnesses and disorders 
http://dx.doi.org/10.11613/BM.2013.021 Biochemia Medica 2013;23(2):172–90
  173
Dobša L, Edozien KC. Copeptin and diseases
where it may help in early detection and diagnos-
tic accuracy. The purpose of this review is to sum-
marize a handful of research done on copeptin 
and to discuss its role as a biological marker in the 
diagnosis and prognosis of various diseases such 
as acute myocardial infarction (AMI), heart failure, 
hyponatremia, sepsis, septic shock, infections of 
lower respiratory tract, acute dyspnea, vasodilato-
ry shock, diabetes insipidus, autosomal dominant 
polycystic kidney disease (ADPKD), diabetes melli-
tus, metabolic syndrome, intracerebral hemor-
rhage, ischemic stroke and head injury.
Copeptin in circulation
Normal values of copeptin in healthy volunteers 
range between 1.70-11.25 pmol/L (6,9,10). Copep-
tin also shows minimal intra-individual variations 
(11). In healthy people, a 28h water deprivation 
leads to a twofold increase in concentration of 
copeptin, while infusion of hypotonic saline induc-
es a 2-3-fold decrease of copeptin concentration 
(11). Copeptin concentration are lower in women 
when compared to men, but there is no signifi cant 
diff erence in copeptin rise between men and 
women with changes in osmolality or volume sta-
tus (3,12,13). Renal function also infl uences copep-
tin concentration in healthy men and this is not 
noticed in healthy women (12). Copeptin has not 
being found to correlate with age or estimated 
glomerular fi ltration rate in healthy subjects, ex-
cept in patients with AMI where copeptin concen-
tration correlates with age and estimated glomer-
ular fi ltration rate (9,12,13). In advanced and acute 
heart failure the rise in copeptin concentration 
goes from 20 pmol/L to 45 pmol/L. In terms of life 
threatening conditions, such as severe sepsis, sep-
tic shock, hemorrhagic shock, ischemic stroke and 
AMI, copeptin increases to concentrations above 
100 pmol/L. On the opposite sphere, copeptin de-
creases in patients with diabetes insipidus, hy-
ponatremia and other conditions associated with 
reduced AVP concentration (13). It is still however 
unknown how copeptin is removed from the cir-
culation. It is assumed that it is partially cleared 
through the kidneys because it is detectable in 
urine (7).
Function of AVP
AVP is a vasoactive neuropituitary hormone. It is 
one of the main hormones of the hypothalamic-
pituitary-adrenal axis and its primary function is 
water regulation and homeostasis of electrolytes. 
The main stimulus for AVP release is hyperosmo-
larity. Hypotension, hypoxia, acidosis, infection, in-
sulin-induced hypoglycemia, pain, nausea, vomit-
ing, certain drugs and other non-specifi c causes of 
stress can also increase concentration of AVP in the 
circulation (3,7).
AVP binds to 3 diff erent receptors, V1a, V1b and V2 
receptor. They are classifi ed into three subtypes 
based on their intracellular transduction mecha-
nisms. The V1a and V1b receptors are associated 
with phosphoinositol turnover, while the V2 recep-
tor activates adenylate cyclase (14). The V1a recep-
tor is widely expressed and mediates AVPs pro-
thrombotic and vasoconstrictor eff ects. Thus, AVP 
agonists are used in treating bleeding and hypo-
tensive disorders (15-17). Through V1a receptor 
FIGURE 1. Schematic presentation of copeptin generation and 
maturation (5).
Synthesis of pre-pro-AVP in the
magnocellular nuclei of the
hypothalamus
Cleavage of the signal peptide
Pro-AVP folds, placing AVP into
a binding pocket of neurophysin
II, protecting it from proteolysis
and promoting high-density
packing in neurosecretory
vesicles
Formation of seven disulfide
bonds within neurophysin II
and one within AVP;
glycosylation of copeptin
Pro-AVP is packaged into
neurosecretory granules
Cleavage that separates
neurophysin II from copeptin
Cleavage of pro-AVP that splits
off AVP
During axonal transport from
the hypothalamic nuclei to the
neutrohypophysis
Processing is complete at the
level of the neurohypophysis
Biochemia Medica 2013;23(2):172–90  http://dx.doi.org/10.11613/BM.2013.021
174
Dobša L, Edozien KC. Copeptin and diseases
AVP also mediates liver glycogenolysis (16,17). The 
V1b receptor is expressed in the pituitary gland 
and pancreas (15,16). Through this receptor AVP 
stimulates the release of adrenocorticotropic hor-
mone. Adrenocorticotropic hormone activates the 
hypothalamic-pituitary-adrenal axis and thus me-
diates a response to stress. Insulin and glucagon 
secretion are mediated via V1b receptor as well 
(16,17). The V2 receptor is expressed in the renal 
collecting ducts and through those receptors the 
antidiuretic eff ect of AVP is mediated (15,16). Phar-
macological blockade of V2 receptor has been 
used to treat hyponatremia and heart failure 
(16,17).
Measurement of AVP and copeptin
Reliable measurement of plasma AVP concentra-
tion is diffi  cult and is subject to preanalytical and 
analytical errors. Such diffi  culties stem from fact 
that AVP is unstable due to its short half-life of 24 
min. To add to this problem, more than 90% of 
AVP in the circulation is bound to platelets, thus 
making accurate measurements very diffi  cult 
(3,6,18,19). Incomplete removal of platelets from 
plasma samples or prolonged storage of unproc-
essed blood samples can lead to falsely elevated 
values of AVP. AVP is also unstable in isolated plas-
ma and serum even when it is stored at -20 °C 
(6,13). The small size of AVP also challenges detec-
tion by sandwich immunoassays and therefore re-
quires the use of less sensitive competitive immu-
noassays (13). All the above mentioned reasons 
contribute to the absence of routine AVP use in 
clinical practice (6).
Unlike AVP, copeptin is stable in EDTA plasma for 
up to 14 days at room temperature, while in citrate 
and heparin plasma copeptin is stable for 7 days 
(19). Its detection doesn’t require extraction or 
other complex preanalytical steps (13). It can easily 
be measured ex vivo by manual or fully automated 
chemiluminescence assays as a replacement bi-
omarker for unstable AVP (1,20,21). Scheme of as-
say for the measurement of copeptin is shown in 
Figure 2. The assay requires minimal serum or plas-
ma volume and the overall time for completing 
the analysis is between 20 and 30 minutes (13). 
Based on these facts, copeptin is suitable for rou-
tine measurements as an alternative to AVP (6). 
Some of the methodology characteristics for cope-
ptin and AVP assays are summarized in Table 1.
FIGURE 2. Scheme of assay for the measurement of copeptin.
TABLE 1. Some of the methodology characteristics for copeptin and AVP assays (21,22).
Copeptin AVP
sandwich immunoassay radioimmunoassy
sensitivity – 2.25 pmol/L sensitivity – 0.5 pg/ml (0.2 µU/ml)
CV < 20% CV – 17%
precise measurement in a range of 2.25–1215 pmol/L sample volume - 1 ml or less
assay linearity at analyte dilutions up to 1:32 complex preanalytic procedures including peptide extraction
COPEPTIN
antibody on tube
solid phase
tracer antibody
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Copeptin as a diagnostic and prognostic 
marker
In stressful situations such as illness, the relation-
ship between plasma osmolality and AVP is lost 
because AVP with corticotropin-releasing hor-
mone (CRH) leads to the production of adrenocor-
ticotropic hormone (ACTH) and cortisol. Serum 
cortisol is proportional to stress levels, and by re-
fl ecting stress levels, cortisol predicts prognostic 
outcome in diff erent diseases. However, cortisol is 
infl uenced by strong circadian rhythm and its 
measurement as a free hormone is demanding. 
These characteristics of cortisol place copeptin as 
a more reliable hormone for determination of 
stress levels. Of note, even mild to moderate stress 
situations contribute to the copeptin release. In re-
cent years copeptin has being studied as a diag-
nostic and prognostic biomarker in various diseas-
es (Table 2). Of mention are acute myocardial inf-
arction, heart failure, acute exacerbation of chronic 
obstructive pulmonary disease, lower respiratory 
tract infections, acute dyspnea, sepsis, hemorrhag-
ic and septic shock, diabetes mellitus, metabolic 
syndrome, hyponatremia, vasodilatory shock, dia-
betes insipidus, autosomal dominant polycystic 
kidney disease (ADPKD), intracerebral hemorrhage, 
ischemic stroke and traumatic brain injury (8,20). 
The data on diagnostic accuracy of copeptin in dif-
ferent disorders are shown in Table 3.
Article; year No. patients Aim Conclusion
Acute miocardial infarction
Gu et al. 
(25); 2011.
145 patients undergoing 
successful primary PCI 
for a fi rst ST-elevation 
AMI presenting within 
12 h of symptom onset
To compare the temporal release 
pattern of copeptin with CK-MB, 
cTnT and hs-cTnT in patients 
with ST-elevation AMI.
Copeptin is elevated in the early hours 
after the onset of an ST-elevation AMI 
when CK-MB and cTnT are still low.
Ray et al.
(24); 2012.
451 patient with a previous 
history of CAD and 
negative cTn at admission
To evaluate the additional value 
of copeptin to conventional cTn 
for a rapid ruling out of AMI in 
patients with acute chest pain 
and a previous history of CAD.
In ED triage of patients with acute chest 
pain suggestive of a non–ST-segment 
elevation AMI and a previous history of 
CAD, the combination of copeptin and 
cTnI allows clinicians to rule out AMI on 
presentation, with an NPV of 98%.
von Haehling
et al. (26); 2012.
2,700 patients (74.1% 
male; AMI, N = 1316; stable 
angina pectoris, N = 1384)
To investigate the prognostic 
value of copeptin with regard 
to mortality and morbidity in 
patients with symptomatic CAD.
Copeptin may help in the prediction 
of major adverse cardiovascular events 
in patients with symptomatic CAD.
Reichlin et al. 
(27); 2009.
487 patients presenting 
to the ED with symptoms 
suggestive of AMI
To examine the incremental value of 
copeptin for rapid rule out of AMI.
The additional use of copeptin seems 
to allow a rapid and reliable rule out 
of AMI already at presentation and 
may thereby obviate the need for 
prolonged monitoring and serial blood 
sampling in the majority of patients.
Meune et al. 
(28); 2011.
58 consecutive patients 
- ACS in 30 patients (AMI 
in 13 patients, unstable 
angina in 17 patients) 
and nonacute coronary 
syndrome in 28 patients
To examine the possible 
incremental value of copeptin 
in the detection of ACS.
A dual marker strategy that combines 
hs-cTnT with copeptin increases slightly 
the detection of ACS at admission.
Lotze et al.
(29); 2011.
142 consecutive patients 
(mean age 71.2 ± 13.5 
years, 76 men)
To test the diagnostic performance of 
the hs-cTnT combined with copeptin 
measurement for early exclusion of AMI.
A single determination of hs-cTnT and 
copeptin may enable early and accurate 
exclusion of AMI in one third of patients, 
even in an ED of a general hospital.
TABLE 2. Overview of the most important references on copeptin.
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Article; year No. patients Aim Conclusion
Keller et al.
(30); 2010. 1386 patients (66.4% male)
To test whether determination 
of copeptin adds diagnostic 
information to cardiac troponin in 
early evaluation of patients with 
suspected myocardial infarction.
In triage of chest pain patients, 
determination of copeptin in addition 
to Tn improves diagnostic performance, 
especially early after CPO. Combined 
determination of Tn and copeptin 
provides a remarkable NPV virtually 
independent of CPO time and therefore 
aids in early and safe rule-out of AMI.
Hernández-
-Romero et al. 
(23); 2012.
122 non-STEACS patients 
without raised TnT, 33 
disease controls and 
43 healthy controls
To investigate whether the use of 
hs-cTnT or copeptin together with 
the association to the classical clinical 
and electrocardiographic parameters 
might help to the better stratifi cation 
and managements as well as in the 
prognosis of patients with non-STEACS. 
hs-cTnT levels increased in non-STEACS, 
were predictive of adverse events and 
could be important for recommending 
an invasive management. A predictive 
role of copeptin out of the fi rst hours 
from admission cannot be confi rmed.
Heart failure
Voors et al. 
(16); 2009.
224 patients with 
symptoms of HF or a 
left ventricular ejection 
fraction < 0.35 after AMI
To compare the prognostic value 
of a copeptin with BNP and 
NT-proBNP on death or a composite 
cardiovascular endpoint in patients 
who developed HF after AMI.
Copeptin is a strong marker for 
mortality and morbidity in patients 
with HF after AMI. In this population, 
the predictive value of copeptin is even 
stronger than BNP and NT-proBNP.
Alehagen et 
al. (31); 2011.
470 elderly patients 
with HF symptoms
To evaluate the association between 
plasma concentrations of copeptin 
combined with concentrations of the 
NT-proBNP and mortality in a cohort of 
elderly patients with symptoms of HF.
Among elderly patients with symptoms 
of HF, elevated concentrations of 
copeptin and the combination of 
elevated concentrations of copeptin 
and NT-proBNP were associated with 
increased risk of all-cause mortality.
Neuhold et al. 
(32); 2010.
181 patients with chronic 
systolic HF after an 
episode of hospitalization 
for worsening HF
To investigate the prognostic role of 
serial measurements of emerging 
neurohormones and BNP in a cohort 
of chronic HF patients undergoing 
increases in HF-specifi c therapy.
In pharmacologically unstable chronic 
HF patients, ba seline values and 
follow-up measures of copeptin, 
midregional proadrenomedullin, 
C-terminal endothelin-1 precursor 
fragment, MR-proANP and BNP were 
equally predictive of all-cause mortality.
Neuhold et al. 
(33); 2008.
786 HF patients from 
the whole spectrum of 
HF (NYHA functional 
class I to IV)
To evaluate the predictive value 
of copeptin over the entire 
spectrum of HF and compare it 
to the BNP and NT-proBNP.
Increased levels of copeptin are 
linked to excess mortality, and this 
link is maintained irrespective of 
the clinical signs of severity of the 
disease. Copeptin is superior to BNP 
or NT-proBNP in this study, but the 
markers seem to be closely related.
Hyponatremia
Fenske et al. 
(34); 2009.
106 consecutive 
hyponatremic patients
To evaluate the diagnostic potential 
of copeptin as a new marker in the 
diff erential diagnosis of hyponatremia.
Copeptin measurement reliably identifi es 
patients with primary polydipsia but has 
limited utility in the diff erential diagnosis 
of other hyponatremic disorders. In 
contrast, the copeptin to U-Na ratio is 
superior to the reference standard in 
discriminating volume-depleted from 
normovolemic hyponatremic disorders.
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Article; year No. patients Aim Conclusion
Nigro et al. 
(35); 2011.
545 patients with suspected 
LRTI and CAP; 509 patients 
with a fi nal diagnosis of 
an ischaemic (N = 362) 
or haemorrhagic stroke 
(N = 40) or transient 
ischaemic attack (N = 107)
To assess copeptin concentrations 
in sick patients with serum sodium 
imbalance of diff erent aetiology 
on admission to the ED.
Plasma copeptin level appears to 
add very little information to the 
work up of sodium imbalance in 
this cohort of medical inpatients. 
It is likely that the nonosmotic 
“stress”-stimulus in acute hospitalised 
patients is a major confounder and 
overrules the osmotic stimulus.
Sepsis and septic shock
Jochberger et 
al. (36); 2009.
10 patients with infection, 
22 with severe sepsis, and 
28 with septic shock
To compare the course of AVP and 
copeptin plasma concentrations 
between patients with infection, 
severe sepsis, and septic shock.
Severe sepsis induced a stronger AVP 
response than infection without systemic 
infl ammation. The lack of a diff erence 
in AVP plasma concentrations between 
patients with and without shock 
indicates that the AVP system does not 
function normally in severe sepsis. 
Infections of lower respiratory tract
Seligman et 
al. (15); 2011. 71 patients with VAP
To compare the predictive value 
of diff erent biomarkers including 
copeptin for mortality in VAP.
The biomarkers procalcitonin, 
MR-proANP, and copeptin can predict 
mortality in VAP, as can the SOFA score.
Boeck et al. 
(38); 2012. 101 patients
To investigate the predictive value of 
the SOFA score and copeptin in VAP.
The predictive value of serial-measured 
SOFA signifi cantly exceeds those 
of single SOFA and copeptin 
measurements. Serial SOFA scores 
accurately predict outcome in VAP.
Müller et al. 
(39); 2007.
545 consecutive 
patients with LRTI and 
50 healthy controls
To investigate circulating levels 
and the prognostic use of 
copeptin for the severity and 
outcome in patients with LRTI.
Copeptin levels are increased with 
increasing severity of LRTI namely in 
patients with CAP and unfavorable 
outcome. Copeptin levels, as a novel 
biomarker, might be a useful tool in the 
risk stratifi cation of patients with LRTI.
Krüger et al. 
(40); 2009.
370 hospitalized patients 
with CAP (85 with antibiotic 
pre-treatment, 285 without 
antibiotic pre-treatment)
To evaluate the infl uence of antibiotic 
pre-treatment on copeptin levels in CAP.
Copeptin serum levels are higher in 
patients without antibiotic pre-treatment 
compared with those with antibiotic 
pre-treatment. Copeptin serum levels 
increase with an increasing severity 
of CAP in patients without, but not in 
patients with, antibiotic pre-treatment.
Seligman et 
al. (42); 2008. 71 patients with VAP
To investigate the correlation of 
copeptin with the severity of septic 
status in patients with VAP and to 
analyze the usefulness of copeptin 
as a predictor of mortality in VAP.
Copeptin levels increase 
progressively with the severity 
of sepsis and are independent 
predictors of mortality in VAP.
Masiá et al. 
(43); 2007. 173 patients
To explore the diagnostic accuracy of 
copeptin and MR-proANP to predict 
mortality in patients with CAP.
Copeptin and MR-proANP may be used to 
predict prognosis in patients with CAP.
Stolz et al. 
(44); 2007. 167 patients with AECOPD 
To assess circulating levels of copeptin, 
CRP and procalcitonin as potential 
prognostic parameters for in-hospital 
and long-term outcomes in patients 
with AECOPD requiring hospitalization.
Copeptin is suggested as a prognostic 
marker for short-term and long-term 
prognoses in patients with AECOPD 
requiring hospitalization.
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Article; year No. patients Aim Conclusion
Acute dyspnea
Potocki et al. 
(45); 2010.
287 patients with 
acute dyspnea
To investigate the prognostic 
value of copeptin alone and 
combined to NT-proBNP in 
patients with acute dyspnea.
Copeptin is a new promising 
prognostic marker for short-term 
mortality independently and 
additive to natriuretic peptide levels 
in patients with acute dyspnea.
Vasodilatory shock
Torgersen et 
al. (46); 2010.
50 critically ill patients 
with advanced 
vasodilatory shock
To evaluate plasma copeptin levels 
before and during exogenous AVP 
infusion and to determine the 
value of copeptin levels before AVP 
therapy to predict complications 
during AVP therapy and outcome 
in vasodilatory shock.
Plasma copeptin levels are elevated in 
patients with advanced vasodilatory 
shock. During exogenous AVP 
therapy, copeptin levels decrease, 
suggesting suppression of the 
endogenous AVP system.
Diabetes insipidus
Katan et al. 
(2); 2007. 38 patients
To study the value of copeptin levels 
in the diagnosis of diabetes insipidus 
during insulin-induced hypoglycemia.
Copeptin measurement may be used 
to assess posterior together with 
anterior pituitary function during 
insulin-induced hypoglycemia.
Kidneys disease
Meijer et al. 
(47); 2011. 102 ADPKD patients
To determine whether endogenous 
AVP concentration is associated with 
disease severity in patients with ADPKD.
On cross-sectional analysis, copeptin 
is associated with disease severity 
in ADPKD patients, supporting the 
results of experimental studies that 
suggest that AVP antagonists have 
a renoprotective eff ect in ADPKD 
and off ering a good prospect for 
clinical studies with these agents.
Diabetes mellitus and metabolic syndrome
Enhörning et 
al. (11); 2010.
4742 individuals (mean age 
58 years; 60% women)
To examine the association of 
increasing quartiles of copeptin (lowest 
quartile as reference) with prevalent 
DM at baseline, insulin resistance and 
incident DM on long-term follow-up.
Elevated copeptin predicts increased 
risk for DM independently of established 
clinical risk factors, including fasting 
glucose and insulin. These fi ndings could 
have implications for risk assessment, novel 
antidiabetic treatments, and metabolic 
side eff ects from AVP system modulation.
Saleem et al. 
(48); 2009.
2490 participants (1293 
AA [64 ± 9 yr], 1197 
NHW [59 ± 10 yr])
To investigate whether plasma copeptin 
is associated with measures of insulin 
resistance and presence of MetS.
Plasma copeptin is cross-sectionally 
associated with measures of 
insulin resistance and MetS.
Enhörning et 
al. (49); 2012.
Baseline examination: 
5131 individuals 
Reinvestigation and end 
points: 2064 individuals
To test whether elevated copeptin 
level is associated with later 
development of the MetS, its individual 
components and microalbuminuria.
Copeptin independently predicts 
DM and abdominal obesity but 
not the cluster of MetS. 
Central nervous system diseases
Yu et al. (17); 
2012.
106 healthy controls, 106 
patients with acute severe 
traumatic brain injury
To investigate the ability of copeptin 
to predict 1-year outcome in patients 
with traumatic brain injury.
Copeptin is a useful, complementary 
tool to predict functional 
outcome and mortality 1 year 
after traumatic brain injury.
Zweifel et al. 
(50); 2010.
40 consecutive patients 
with spontaneous ICH
To test the hypothesis that high 
copeptin levels in acute hemorrhagic 
stroke patients are also associated with 
mortality and poor functional outcome.
Copeptin is a new prognostic marker in 
patients with an ICH. If this fi nding can 
be confi rmed in larger studies, copeptin 
might be an additional valuable tool for 
risk stratifi cation and decision-making 
in the acute phase of ICH.
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Article; year No. patients Aim Conclusion
Zhang et al. 
(51); 2012.
50 healthy controls, 
89 patients with acute 
spontaneous basal 
ganglia hemorrhage
To evaluate the relation of plasma 
copeptin levels to long-term 
outcome and early neurological 
deterioration after ICH.
Increased plasma copeptin level 
is an independent prognostic 
marker of 1-year mortality, 1-year 
unfavorable outcome and early 
neurological deterioration after ICH.
Dong et al. 
(52); 2011.
30 healthy controls, 86 
patients with acute ICH
To investigate changes in plasma 
copeptin levels in patients during the 
initial 7-day period after ICH and also 
determine whether copeptin is an 
independent prognostic marker of 
mortality in a group of ICH patients.
Increased plasma copeptin level is 
associated with hematoma volume 
and an independent prognostic 
marker of mortality after ICH.
Zhu et al. (53); 
2011.
303 patients with an initial 
diagnosis of aneurysmal 
SAH
To investigate the ability of copeptin 
to predict the disease outcome and 
cerebrovasospasm in the patients with 
SAH.
Copeptin level is a useful, complementary 
tool to predict functional outcome and 
mortality after SAH.
PCI - percutaneous coronary intervention; CAD - coronary artery disease; ED - emergency department; ACS - acute coronary syndrome; CPO - 
chest pain onset; non-STEACS - ACS without ST-segment elevation; HF - heart failure; DM - diabetes mellitus; U-Na - Na levels in urine; LRTI - lower 
respiratory tract infection; SOFA - Sequential Organ Failure Assessment; MR-proANP - midregional proatrial natriuretic peptide; AECOPD - acute 
exacerbation of chronic obstructive pulmonary disease; AA - African-Americans; NHW - non-Hispanic whites; MetS - metabolic syndrome; SAH - 
aneurysmal subarachnoid hemorrhage
TABLE 3. Diagnostic accuracy of copeptin in diff erent disorders.
Article year Result
Acute miocardial infarction
Ray et al.
(24); 2012.
A negative cTnT combined with a copeptin value lower than 10.7 pmol/L at presentation was able to rule out AMI 
with a NPV of 98% (95% CI, 95-99%).
von Haehling et 
al. (26); 2012.
Calculated AUC for copeptin of 0.703 (95%CI: 0.681–0.725) for the composite endpoint after three months 
(myocardial reinfarction, stroke, all-cause death), and 0.770 (95%CI: 0.736–0.803) for all-cause death. A cutoff  
value of 21.6 pmol/L for the composite endpoint yielded a sensitivity of 56.3% and a specifi city of 78.6%.
Reichlin et al. 
(27); 2009.
Copeptin levels were signifi cantly higher in AMI patients compared with those having other diagnoses (median 
20.8 pmol/L vs. 6.0 pmol/L, P < 0.001). The AUC for troponin T and copeptin at initial presentation was 0.97 
(95% CI: 0.95-0.98), and for troponin T alone 0.86 (95% CI: 0.80-0.92) (P < 0.001). A copeptin level < 14 pmol/L in 
combination with a troponin T ≤ 0.01 µg/L correctly ruled out AMI with a sensitivity of 98.8% and a NPV of 99.7%.
Meune et al. 
(28); 2011.
The combination of copeptin with hs-cTnT for determination of patients with ACS on admission provided a NPV 
of 82.6%. The AUC was 0.90 for hs-cTnT measured on admission, and 0.94 if repeated at 3 hours and 6 hours or 
combined with copeptin measurement at admission (non-signifi cant diff erence).
Lotze et al.
(29); 2011.
A hs-cTnT level of < 0.014 µg/L in combination with copeptin < 14 pmol/L at initial presentation ruled out AMI in 
31.7% of patients, each with a sensitivity and NPV of 100%.
Keller et al. 
(30);2010.
Combined measurement of copeptin and TnT on admission improved the c-statistic from 0.84 for TnT alone to 
0.93 in the overall population and from 0.77 to 0.9 in patients presenting within 3 h after CPO (P < 0.001). The 
combination of copeptin with a conventional TnT provided a NPV of 92.4%.
Heart failure
Voors et al.
(16); 2009.
Copeptin (AUC 0.81) is a stronger predictor of mortality compared with BNP (AUC 0.66; P = 0.006 vs. copeptin) 
and NT-proBNP (AUC 0.67; P = 0.002 vs. copeptin).
Alehagen et al. 
(31); 2011.
In a ROC analysis of cardiovascular mortality using the 10-year follow-up period, the AUC increased from 0.70 
to 0.76 (95% CI, 0.71-0.82) by adding copeptin concentration to clinical examination variables and NT-proBNP 
concentration.
Neuhold et al. 
(33); 2008.
The AUC with respect to 2-year all-cause mortality in HF patients was 0.711 for BNP and 0.711 for copeptin. The 
predictive power increased to an AUC of 0.744 if both variables were added in one model.
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Hyponatremia
Fenske et al. 
(34); 2009.
The copeptin to U-Na ratio exhibited a good diagnostic utility identifying SIADH with an AUC of 0.88 (95% 
CI: 0.81–0.95; P < 0.001). Choosing a cutoff  value of less than 30 pmol/mmol, the copeptin to U-Na ratio had a 
sensitivity of 85%, specifi city of 87%, PPV of 85%, and NPV of 86% for SIADH.
Infections of lower respiratory tract
Seligman et al. 
(15); 2011.
Copeptin accuracy in predicting mortality in VAP: on the day of VAP onset (sensitivity 0.69, specifi city 0.69, AUC 
0.70 (95% CI: 0.57-0.82), PPV 0.56, NPV 0.80, LR+ 2.23, LR- 0.45); on the fourth day (sensitivity 0.80, specifi city 0.60, 
AUC 0.72 (95% CI: 0.59-0.84), PPV 0.53, NPV 0.84, LR+ 2.00, LR- 0.33)
Boeck et al. (38); 
2012.
The AUC of copeptin at VAP onset was 0.67 (95% CI: 0.53-0.81), and that of mean copeptin was 0.70 (95% CI: 
0.57-0.84). The AUC values of the combination SOFA-copeptin at VAP onset (0.73; 95% CI: 0.60-0.87) and of the 
combination SOFA mean–copeptin mean (0.89; 95% CI: 0.80-0.99) were not superior as compared with the AUC 
value of SOFA.
Müller et al. (39); 
2007.
In patients with CAP, the AUC of copeptin to predict survival was 0.68 (0.63–0.73). To diff erentiate CAP from other 
LRTIs, copeptin had an AUC of 0.73 (0.69–0.76). Thereby, with the optimal cut-off  of 22.7 pmol/L, sensitivity was 
66.5% and specifi city was 68.7%. To achieve 90% sensitivity, the cut-off  for copeptin was 9 pmol/L with specifi city 
of 39%.
Seligman et al. 
(42); 2008.
The AUC for copeptin to predict mortality in VAP patients on the day VAP was suspected, was 0.70. For a 
threshold of 64.8 pmol/L, the sensitivity was 0.69 and the specifi city was 0.69. The AUC for copeptin on the fourth 
day of treatment was 0.72. Using a cutoff  level of 43.0 pmol/L, the sensitivity was 0.80 and the specifi city was 0.60.
Acute dyspnea
Potocki et al. 
(45); 2010.
The AUC for copeptin to predict 30-day mortality in patients with acute dyspnea was 0.83 (95% CI: 0.76-0.90), 
with an optimal cut-point of 59 pmol/L. Copeptin had a signifi cantly higher AUC compared with BNP (P = 
0.002) but not compared to NT-proBNP (P = 0.21). In patients with ADHF the AUC for copeptin was 0.84 (95% CI: 
0.76-0.92), (copeptin vs. NT-proBNP P = 0.098; copeptin vs. BNP P < 0.001).
Vasodilatory shock
Torgersen et al. 
(46); 2010.
Copeptin levels at randomization predicted the occurrence of ischemic skin lesions (AUC 0.73; P = 0.04), a fall in 
platelet count (AUC 0.75; P = 0.01) during AVP and intensive care unit mortality (AUC 0.67; P = 0.04).
Diabetes insipidus
Katan et al.
(2); 2007.
A basal copeptin level less than 2.59 pmol/L had 89% sensitivity and 76% specifi city to detect diabetes insipidus. 
A stimulated copeptin level 45 min after insulin injection less than 4.75 pmol/L had 100% sensitivity and 100% 
specifi city to detect diabetes insipidus. Copeptin levels 30 and 90 min after insulin injection had an AUC to detect 
diabetes insipidus of 0.94 and 0.98, respectively.
Diabetes mellitus and metabolic syndrome
Enhörning et al. 
(11); 2010.
In subjects free of DM at baseline, the AUC increased from 0.694 to 0.710 (P = 0.08) when copeptin was added 
to the personal model and from 0.832 to 0.841 (P = 0.007) when copeptin was added to the clinical model of 
diabetes prediction. In subjects free of IFG at baseline, the AUC increased from 0.663 to 0.713 (P = 0.03) and 
from 0.783 to 0.805 (P = 0.04) when copeptin was added to the personal model and clinical model for diabetes 
prediction, respectively.
Saleem et al. 
(48); 2009.
In multivariable logistic regression analyses that adjusted for age and sex, plasma copeptin levels in the third and 
fourth quartile were signifi cantly associated with a higher odds of having metabolic syndrome: OR of 1.81 (P < 
0.001) and 1.91 (P < 0.001), respectively. In the subset of participants without diabetes, having a plasma copeptin 
level in the third or fourth quartile was signifi cantly associated with the presence of metabolic syndrome (OR 
1.83, P < 0.001; OR 1.82, P = 0.001, respectively) after adjustment for age and sex.
Enhörning et al. 
(49); 2012.
After additional adjustment for all the MetS components at baseline, increasing copeptin quartiles predicted 
incident abdominal obesity (OR 1.55, 1.30 and 1.59; P for trend = 0.04), DM (OR 1.18, 1.32 and 1.46; P for trend 
= 0.04) and microalbuminuria (OR 1.05, 1.08 and 1.65; P for trend = 0.02) but not MetS (P for trend = 0.19) at the 
reexamination.
Central nervous system diseases
Yu et al.
(17); 2012.
AUC identifi ed that a baseline plasma copeptin level > 540.9 pg/mL predicted 1-year unfavorable outcome 
of patients with 75.0% sensitivity and 91.4.0% specifi city (AUC 0.905; 95% CI: 0.833–0.953) and that a baseline 
plasma copeptin level > 503.6 pg/mL predicted 1-year mortality of patients with 90.3% sensitivity and 77.3% 
specifi city (AUC 0.909; 95% CI: 0.837–0.956).
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Zweifel et al. 
(50); 2010.
For the prediction of death, ROC analysis revealed an AUC for copeptin of 0.88 (95%CI: 0.75-1.00). The predictive 
value of the copeptin concentration was thus similar to that of GCS (AUC 0.82 (95%CI; 0.59-1.00) P = 0.53), of the 
ICH Score (AUC 0.89, (95%CI: 0.76-1.00), P = 0.94) and the ICH Grading Scale (AUC 0.86 (95%CI: 0.69-1.00), P = 0.81).
Zhang et al. (51); 
2012.
A multivariate analyses selected NIHSS score (OR = 1.219; 95% CI: 1.148–1.498; P < 0.001) and baseline plasma 
copeptin level (OR = 1.138; 95% CI: 1.063–1.345; P < 0.001) as the independent predictors for 1-year mortality. 
A multivariate analyses selected NIHSS score (OR = 1.385; 95% CI: 1.211–1.680; P < 0.001) and baseline plasma 
copeptin level (OR = 1.191; 95% CI: 1.102–1.323; P < 0.001) as the independent predictors for 1-year unfavorable 
outcome. A multivariate analyses selected NIHSS score (OR = 1.321; 95% CI: 1.140–1.430; P < 0.001) and baseline 
plasma copeptin level (OR = 1.217; 95% CI: 1.139–1.398; P < 0.001) as the independent predictors for early 
neurological deterioration.
Dong et al.
(52); 2011.
A multivariate analysis showed that plasma copeptin level was an independent predictor for 1-week mortality 
(OR = 1.013; 95% CI: 1.003–1.023; P = 0.009) and positively associated with hematoma volume (t = 6.616, P < 0.001). 
The AUC identifi ed that a baseline plasma copeptin level > 577.5 pg/mL predicted 1-week mortality with 87.5% 
sensitivity and 72.2% specifi city (AUC = 0.873; 95% CI: 0.784–0.935).
Zhu et al.
(53); 2011.
A cutoff  value of 20.5 pmol/L for copeptin predicted 1-year mortality with 92.8% sensitivity and 70.1% specifi city 
(AUC 0.868 ± 0.036; P < 0.001), a cutoff  value of 28.7 pmol/L predicted in-hospital mortality with 78.1% sensitivity 
and 89.7% specifi city (AUC 0.868 ± 0.042; P < 0.001), a cutoff  value of 23.4 pmol/L predicted cerebrovasospasm 
with 69.2% sensitivity and 84.9% specifi city (AUC 0.792 ± 0.027; P < 0.001) and a cutoff  value of 23.8 pmol/L 
predicted 1-year poor neurologic outcome with 82.2% sensitivity and 79.8% specifi city (AUC, 0.860 ± 0.026; P < 
0.001).
CI - confi dence interval; AUC - area under the curve; P - predictive value; CPO - chest pain onset; ROC - receiver operating characteristic curve; HF 
- heart failure; U-Na - Na levels in urine; LR+ - positive likelihood ratio; LR- - negative likelihood ratio; SOFA - Sequential Organ Failure Assessment; 
LRTI - lower respiratory tract infection; ADHF - acute decompensated heart failure; DM - diabetes mellitus; IFG – impaired fasting glucose; OR - 
odds ratio; MetS - metabolic syndrome; GCS – Glasgow Coma Scale score; NIHSS - National Institutes of Health Stroke Scale
Copeptin in acute myocardial infarction
Acute myocardial infarction (AMI) is a major cause 
of death in industrialized countries. Its prevalence 
in third-world countries is also steadily rising. 
Therefore, it is extremely important to ensure early 
detection and diagnostic accuracy. These abilities 
will aid rapid interventions in AMI and prevent pre-
mature discharge of unrecognized AMI patients 
from the emergency department (13). The most 
important methods in the diagnosis of AMI are 
electrocardiography (ECG) and determination of 
serum cardiac troponin T (cTnT) concentration, 
which complement clinical assessment. Cardiac Tn 
is superior to other biomarkers available for AMI 
diagnosis, including myoglobin, MB fraction of 
creatine kinase (CK-MB), myeloperoxidase and 
heart fatty acid-binding protein (23). Despite these 
methods and biomarkers, the exclusion of AMI is 
still demanding. ECG is of little help in the exclu-
sion of AMI because one quarter to one third of 
patients with AMI show no signifi cant ECG chang-
es in the presence of ongoing acute cardiac 
ischemia. However, ECG is necessary for identifi ca-
tion of patients with ST-segment elevation (24). 
Conventional cardiac biomarkers, such as CK-MB 
and TnT, are unable to aid in rapid exclusion of AMI 
in patients presenting early in the hospital with 
symptoms suggestive for AMI. This is due to the 
fact that their concentrations do not increase dur-
ing the fi rst few hours of AMI (25). Therefore, the 
exclusion of AMI requires monitoring of patients 
between a 6 to 9 hour period and serial blood 
sampling for measurement of cTnT concentration 
(24,26,27).
In order to increase the accuracy for detection of 
AMI, a highly sensitive cardiac troponin T (hs-cTnT) 
has been developed, which allows measurement 
of concentrations that are 10 times lower than the 
previous ones. This assay allows greater accuracy 
and earlier detection of AMI (28,29). However, de-
spite its ability for earlier diagnosis of AMI, there is 
still a “troponin-blind” interval after the onset of 
chest pain still due to delayed troponin release 
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(29). A use of this assay enables detection of myo-
cardial injury due to a broad spectrum of patholo-
gies which includes myocardial ischemic and myo-
cyte physiologic remodeling. It increases the 
number of positive tests on admission as com-
pared to the less sensitive assays which compli-
cates triage and management of patients with 
chest pain (13).
If the organism is exposed to endogenous stress 
such as AMI, this activates the AVP system and 
copeptin is excreted into circulation independent 
of necrosis of cardiac cells (28). Also, inadequate 
fi lling of the left ventricle caused by AMI stimulates 
cardiac baroreceptors or causes direct damage to 
baroreceptors which subsequently leads to AVP 
and copeptin secretion from the posterior pitui-
tary gland (13). After the onset of chest pain copep-
tin is elevated within 3-4 hours, reaching a peak 
value in the fi rst day (26,29). During the second 
day they slowly start to decrease reaching a pla-
teau after 3-5 days (29). From the pathophysiologi-
cal aspect, decreasing concentration of copeptin 
just a day after myocardial ischemia may indicate 
adjustment to neurohumoral stress by activation 
of AVP system after AMI (29). A decrease in copep-
tin concentration may also be due to the cessation 
or at least a reduction of chest pain after the onset 
of AMI, or they may as well be an inter-play of both 
reasons (27). Copeptin rises at a time when other 
biomarkers are still undetectable (25,27). CK-MB, 
TnT and hs-cTnT concentrations reach peak values 
after more than 14 hours and return to their nor-
mal values slower (25). Copeptin is more sensitive 
than cTnT and myoglobin within the fi rst 3 hours 
of AMI detection. The sensitivity of copeptin is 
75.2% (cutoff  > 9.8 pmol/L), cTnT 43% (cutoff  > 0.03 
μg/L) and myoglobin 62.3% (cutoff  > 107 ng/mL) 
(30). However, in the fi nal exclusion of AMI, copep-
tin is not able to replace cTnT, but only enables 
making earlier decisions in clinical practice (30). 
The combination of copeptin and cTn, compared 
with only cTn, improves diagnostic accuracy of AMI 
reaching a sensitivity of 85.1% and a negative pre-
dictive value (NPV) of 92.4% within 3 hours from 
the onset of chest pain. The highest sensitivity and 
NPV were achieved with 9.8 pmol/L as the cutoff  
representing the 95th percentile (30). Reichlin et al. 
reported even a greater sensitivity and NPV using 
both markers in exclusion of AMI. A copeptin con-
centration < 14 pmol/L in combination with a TnT 
≤ 0.01 µg/L rules out AMI at presentation with a 
sensitivity of 98.8% and a NPV of 99.7% (27). There-
fore, such combination of biomarkers would ena-
ble fast and accurate exclusion of AMI at an early 
stage of presentation without the need for serial 
blood sampling (24). This strategy of using more 
biomarkers (cTnT or hs-cTnT for detection and 
quantifi cation of myocardial necrosis, and copep-
tin for quantifi cation of endogenous stress) to as-
sess the outcome after AMI has an advantage be-
cause it includes various pathological pathways 
and may be of prognostic signifi cance (14,23,25, 
27).
In a recent study Lotze et al. reported a positive 
correlation between hs-cTnT and copeptin at the 
time of initial AMI presentation (r = 0.41; P < 0.001). 
Cut-off  value of 0.014 µg/L for hs-cTnT can be used 
for fast exclusion of AMI with a sensitivity of 92.3%, 
specifi city of 53.5%, positive predictive value (PPV) 
of 16.7% and NPV of 98.6%. The corresponding 
values for copeptin are 69.2%, 47.3%, 11.7% and 
93.9%, respectively. Cut-off  value of 0.014 µg/L for 
hs-cTnT in combination with a copeptin value of < 
14 pmol/L at admission exclude AMI with a sensi-
tivity of 100%, specifi city of 34.9%, PPV of 13.4% 
and NPV of 100%, indicating that this combination 
of biomarkers has a higher diagnostic accuracy 
than use of only hs-cTnT or copeptin. By measuring 
hs-cTnT with copeptin, AMI could be ruled out with 
a NPV of 100% in one third of patients who have 
symptoms which indicate to AMI (29). In addition, 
Meune et al. reported that the combination of hs-
cTnT and copeptin at admission compared with 
use of only hs-cTnT increased detection of acute 
coronary syndrome (ACS) on the level which is 
similar to serial measurement of hs-cTnT. The com-
bination of hs-cTnT and copeptin at admission ex-
cludes ACS with a sensitivity of 86.7% and NPV of 
82.6% (hs-cTnT value of 0.014 μg/L is the 99th per-
centile of the assay; cut-off  value of copeptin is 14 
pmol/L). The sensitivity of only hs-cTnT measured 
at admission was 73.3% and NPV was 76.5%, while 
sensitivity and NPV of hs-cTnT measured after 3 
hours were 83.3% and 83.9%, respectively (28).
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Copeptin concentration is signifi cantly higher in 
patients with suspected ACS with fi nal diagnosis 
of AMI compared to patients with suspected ACS 
with a diff erent fi nal diagnosis. These diagnoses 
include unstable angina and other cardiac and 
non-cardiac causes of chest pain (25). Patients with 
unstable angina have similar copeptin concentra-
tion like patients with other causes of chest pain 
(27). Therefore, ischemia, as long as not accompa-
nied by necrosis (e.g. unstable angina), does not 
cause higher secretion of copeptin than other 
causes of chest pain. Also, copeptin cannot dis-
criminate patients with unstable angina from pa-
tients with non ischemic chest pain (27).
Copeptin and heart failure
Currently there are several neurohormones which 
are used as biomarkers for diagnosis, prognosis 
and clinical decision in chronic heart failure. The B-
type natriuretic peptide (BNP) and N-terminal 
proBNP (NT-proBNP) are the most common. They 
are released in the circulation when cardiac stretch-
ing occurs and they are powerful prognostic bi-
omarkers of heart failure outcome (19,31). But de-
spite these biomarkers, it is considered that heart 
failure is not detected in up to 50% of patients, so 
diagnosis of this disease remains a major challenge 
(31). Therefore, scientifi c research has lately been 
directed towards fi nding new biomarkers that can 
improve the diagnosis and prognosis of heart fail-
ure.
It is noticed that AVP concentration is increased in 
patients with chronic heart failure (16,19,31). Since 
AVP secretion is partially stimulated in response to 
a high osmolality, there are still unanswered ques-
tions as to why we fi nd an increase of AVP in pa-
tients with heart failure who generally have a low-
er osmolality (16,31). There are several possible ex-
planations for this increase. The release of AVP in 
heart failure is mainly stimulated by reduced car-
diac output, and in turn insuffi  cient fi lling of arter-
ies leads to carotid sinus and aortic arch barore-
ceptor activation. It seems that in heart failure, AVP 
secretion caused by osmolarity stimulus is overrid-
den by the non-osmolarity stimulus, which leads 
to hypo-osmolality. Some studies showed that hy-
ponatremia, which is often present in patients with 
heart failure, might also stimulate the release of 
AVP. It is also known that angiotensin II increases 
concentration of AVP. In heart failure angiotensin II 
is elevated even in the presence of ACE inhibitors 
(16,19).
AVP serves as a parameter of disease severity and 
it appears to have a role in the pathology of heart 
failure as well. AVP by stimulation of V1a receptors 
increases protein synthesis in myocytes, it stimu-
lates the development of myocardial hypertrophy 
and decreases heart contractility and also stimu-
lates cardiac fi broblasts, and thus promotes myo-
cardial fi brosis. Increased release of AVP is also as-
sociated with increased preload, increased fi lling 
pressures and increased afterload (31). High copep-
tin concentration which refl ects rise of AVP in the 
blood therefore predicts poor prognosis in pa-
tients with chronic heart failure (16,18). Copeptin is 
a good predictor of death or heart failure within 
60 days, helping to classify patients into groups of 
low, medium and high risk. It is also independent 
of already established conventional risk factors for 
heart failure (16,20). Copeptin is not only impor-
tant for short-term prognosis but is also important 
in identifying patients with long-term risk. In-
creased copeptin concentration in elderly patients 
with symptoms of heart failure is associated with 
increased risk of mortality after a follow-up of 13 
years (20).
Copeptin refl ects diff erent pathological pathways 
that lead to a deterioration of heart failure than 
BNP or NT-proBNP, so when copeptin is combined 
with BNP or NT-proBNP, predicting disease out-
come can be improved (19). Some studies indicate 
the equal prognostic value of copeptin, BNP and 
NT-proBNP in predicting mortality, whereas some 
studies give a better prognostic value to copeptin 
(14,16,19,32,33). A possible explanation for better 
prognostic value of copeptin is that BNP and NT-
proBNP, unlike copeptin, correlate with age and re-
nal function. Also there is large variation in BNP in 
plasma over time in chronic heart failure. However, 
the combined measurement of plasma copeptin 
and NT-proBNP certainly provides more valuable 
information than the measurement of only one bi-
omarker (14,16).
Biochemia Medica 2013;23(2):172–90  http://dx.doi.org/10.11613/BM.2013.021
184
Dobša L, Edozien KC. Copeptin and diseases
Neuhold et al. investigated the predictive ability of 
copeptin for the entire spectrum of heart failure, 
including patients with New York Heart Associa-
tion (NYHA) functional class I to IV. They reported 
that copeptin at all symptomatic stages of heart 
failure was independently associated with mortal-
ity, and it was the most powerful predictor of 
death in II and III NYHA class. However, it is note-
worthy that for asymptomatic patients (NYHA 
functional class I) rate of events was too low to en-
sure information in this cohort. For patients in the 
most severe stage of heart failure (NYHA function-
al class IV) copeptin has provided additional inde-
pendent information, but was inferior to the val-
ues of sodium and glomerular fi ltration (33).
Copeptin and hyponatremia
Distinguishing patients with syndrome of inappro-
priate antidiuretic hormone secretion (SIADH) from 
patients with hyponatremia in clinical practice is a 
diagnostic challenge. Measuring copeptin concen-
tration is not reliable enough to diff erentiate these 
two conditions due to large overlaps in values of 
copeptin, even though mean values of copeptin 
are higher in patients with hyponatremia com-
pared to patients with SIADH (34). However, it has 
been proven that the ratio of copeptin in serum 
and sodium in urine is diagnostically very useful 
(34). This ratio can be used in diff erentiating nor-
movolemic hyponatremia (ratio ≤ 30 pmol/mmol) 
as SIADH, from hypovolemic hyponatremia (ratio 
> 30 pmol/mmol), i.e. in diff erentiation of inappro-
priate from appropriate secretion of AVP (15,34).
Higher copeptin concentration is seen in patients 
with hyponatremia during chronic renal failure 
compared to patients with gastrointestinal loss. 
This is probably due to several reasons, such as ac-
tivation of the AVP system in patients with im-
paired renal function, abundance of receptors for 
AVP in renal tubules, and the fact that copeptin is 
excreted from the body via the kidneys (35). Meas-
uring copeptin concentration in plasma of patients 
with acute illnesses seems to provide little infor-
mation about sodium imbalance because copep-
tin concentration is similar in diff erent etiologies of 
sodium imbalance. It is worth mentioning that 
though copeptin concentration may be similar in 
diff erent etiologies, it may still contribute to un-
derstanding the pathophysiology of various caus-
es of hyponatremia (35).
Copeptin, sepsis and septic shock
AVP and copeptin are also elevated in sepsis and 
septic shock (4,6,36). Jochberger et al. reported 
that AVP concentration is higher in patients with 
sepsis compared to patients with infections with-
out systemic infl ammation. AVP secretion can be 
induced by infl ammatory mediators such as inter-
leukin 1, tumor necrosis factor α and several other 
factors such as acidosis, pain, hypoxia or neuroen-
docrine stress. These latter factors are also likely to 
occur in patients with severe sepsis than in pa-
tients with infections without systemic infl amma-
tion (36). In this study, AVP values did not diff er be-
tween patients with severe sepsis with shock and 
those without shock, or between surviving pa-
tients and those who didn’t survive. In septic shock 
higher values of AVP are expected because of re-
duced venous fi lling as well as arterial hypotension 
which stimulate the release of AVP. However, dur-
ing severe sepsis and primarily during septic shock, 
AVP system is partially dysfunctional and relative 
AVP defi ciency contributes to the inability to es-
tablish vascular tone in patients with septic shock. 
Proposed mechanisms for possible sepsis associ-
ated dysfunction of AVP system include autonom-
ic dysfunction of aff erent pathways and inade-
quate production of AVP with consequent deple-
tion of storage in the neuro-hypophysis. In pa-
tients with severe sepsis AVP in plasma is associat-
ed with serum osmolarity, arterial pH, oxygen par-
tial pressure and arterial lactate, whereas in pa-
tients with septic shock AVP is associated only with 
serum osmolarity (36).
In sepsis and septic shock signifi cantly higher plas-
ma copeptin has been noticed as well. Although 
there is an excellent correlation between copeptin 
and AVP in diff erent diseases, their correlation in 
severe sepsis and septic shock is smaller. The need 
for continuous veno-venous hemofi ltration (CV-
VHF) worsens the correlation between copeptin 
and AVP, suggesting that diff erent sieving coeffi  -
cients may result in diverse amounts of fi ltered 
hormone levels during CVVHF. Infl ammation can 
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also interfere with the relationship between AVP 
and copeptin (36). Unlike the AVP whose values 
don’t diff er in patients with sepsis who survived 
and those who didn’t survive, copeptin is higher in 
non-survivors compared to survivors (15,36,37). 
This suggests that copeptin could represent a 
prognostic biomarker in sepsis (15,37).
Copeptin and infections of lower respiratory 
tract
In infections of lower respiratory tract, gas ex-
change in the lungs causes changes in AVP system 
(38). Endotoxins and acute phase cytokines (e.g. IL-
1β, IL-6, TNF-α) which are present during respira-
tory infections also stimulate the secretion of AVP 
(39). However, AVP also has an important role in 
regulation of the hypothalamic-pituitary-adrenal 
axis through which it mediates its response to 
stress in diseases (39). Copeptin is cosynthesized 
with AVP, it is found in equimolar amounts with 
AVP in the circulation, and therefore copeptin con-
centration is signifi cantly higher than in healthy in-
dividuals. Copeptin concentration was measured 
in patients with community-acquired pneumonia 
(CAP), ventilator associated pneumonia (VAP), 
acute bronchitis and chronic obstructive pulmo-
nary disease (COPD). It was found that in those dis-
eases copeptin concentration increased with the 
severity of the disease (15,39-42). It has been 
shown that copeptin is an independent predictor 
of mortality in VAP (15,40-42). Due to the complex-
ity of AVP eff ects in VAP, the diff erence in copeptin 
concentration according to survival status is small, 
and therefore cannot be defi ned with a clear cut-
off  value. Biomarker that predicts the outcome of 
a disease should be elevated in that disease com-
pared to healthy individuals, and it must refl ect 
the degree of organ dysfunction and overall health 
condition. Boeck et al. reported that copeptin ful-
fi lls the fi rst two criteria, but lacks considerably in 
the third criterion. Therefore, its predictive power 
is lost in the heterogeneous picture of VAP (38).
In CAP copeptin is the only biomarker that is an in-
dependent predictor of this disease, and may pro-
vide additional information about the severity of 
disease. Due to its high NPV, copeptin may help in 
identifying patients with low risk of death. Since it 
is independent of patient’s age, it can be a valua-
ble prognostic factor in young patients with CAP 
(43). Despite its very good prognostic value, copep-
tin gives little information about predicting the 
etiology of CAP because there is considerable 
overlap in copeptin values between patients with 
diff erent etiologies of pneumonia (43). Krüger et al. 
reported that it is clinically important to consider 
antibiotic therapy for correct interpretation of 
copeptin concentration as well as concentration of 
other infl ammatory biomarkers in CAP, because 
patients treated with antibiotics showed signifi -
cantly lower copeptin values compared to those 
who didn’t take antibiotics before admission to 
the hospital, which can be explained by reduced 
circulation damage caused by sepsis (40).
In severe chronic obstructive pulmonary disease 
(COPD) AVP has a vasoconstrictive eff ect. At insuf-
fi cient tissue oxygenation this response makes car-
diovascular adaptation easier through elevated 
AVP concentration. Elevated AVP compensates for 
insuffi  cient activation of V1 receptors after expo-
sure to ongoing hypoxemia. It is also considered 
that in pulmonary hypertension AVP creates a 
negative inotropic eff ect on the right ventricle and 
increases pulmonary vasoconstrictive response in 
endotoxemia. This could link increased AVP and 
copeptin with poor clinical outcome in COPD (40). 
Compared with CRP and procalcitonin, copeptin is 
superior in predicting the course of COPD exacer-
bation. Elevated copeptin concentration predicts 
the fi nal outcome in patients with acute exacerba-
tion of COPD and serves as a risk factor for long-
term clinical failure, regardless of age, comorbidity, 
hypoxemia or functional pulmonary disorder (44).
Müller et al. compared copeptin values in various 
etiologies of lower respiratory tract infections and 
reported that copeptin concentration in patients 
with acute bronchitis and acute exacerbation of 
COPD was signifi cantly higher compared to con-
trol group. On further examination it was also dis-
covered that there was no diff erence in copeptin 
concentration between acute bronchitis and acute 
exacerbation of COPD. Also, patients who were di-
agnosed with CAP had the highest copeptin con-
centration. Only slightly elevated copeptin con-
centration in acute bronchitis and acute exacerba-
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tion of COPD compared to control group probably 
refl ects localized infection (39).
Copeptin and acute dyspnea
The identifi cation of dyspneic patients at the high-
est risk for adverse outcomes is diffi  cult because 
acute dyspnea often occurs due to several reasons 
such as cardiac, pulmonary or infl ammatory caus-
es (45). In these patients copeptin secretion is 
probably connected with three possible mecha-
nisms. Firstly, AVP released in heart failure is main-
ly driven by inadequate fi lling of arteries which ac-
tivates the carotid sinus and aortic arch barorecep-
tors. Secondly, in severe COPD AVP has vasocon-
strictive eff ect which is induced by hypoxia. Ele-
vated concentration of AVP can compensate for 
the inadequate regulation of V1 receptors after ex-
posure to ongoing hypoxemia. Finally, copeptin is 
signifi cantly elevated in bacterial infection and fe-
brile conditions (45).
Potocki et al. pointed out that copeptin concentra-
tion is signifi cantly higher in patients with acute 
decompensated heart failure (ADHF) compared to 
patients with other diagnoses responsible for 
acute dyspnea. Also, in that study, copeptin was 
signifi cantly higher in patients who did not survive 
compared to patients who survived at 30 days, re-
gardless of the presence of ADHF. Therefore, 
copeptin could be a promising prognostic biomar-
ker for short term mortality in patients with acute 
dyspnea and even more in patients with ADHF. 
Copeptin is also independent of natriuretic pep-
tides values (45).
Copeptin and vasodilatory shock
Copeptin concentration in plasma is elevated in 
patients with severe vasodilatory shock. These el-
evated copeptin refl ects the severity of the dis-
ease, a higher incidence of complications and a 
greater risk of death. AVP is infused in patients 
with severe vasodilatation with the intention of 
supplementing a lack of endogenous AVP and re-
ducing the use of potentially high and toxic doses 
of catecholamine. During therapy with exogenous 
AVP, copeptin concentration is decreased, suggest-
ing the suppression of endogenous AVP system. 
High copeptin before treatment and the extent of 
decrease of copeptin during treatment with exog-
enous AVP is associated with severity of disease 
and mortality (46).
Copeptin and diabetes insipidus
AVP is released into the circulation after hypoglyc-
emic stimulus. Insulin-induced hypoglycemia is 
used as a standardized procedure to assess the in-
tegrity of the hypothalamic-pituitary-adrenal axis. 
In patients with normal pituitary function, insulin-
induced hypoglycemia leads to a threefold in-
crease of AVP concentration. Since copeptin 
strongly correlates with AVP, copeptin can sepa-
rate healthy people from patients with diabetes 
insipidus. Copeptin concentration measured 45 
minutes after injection of insulin has the best sen-
sitivity and specifi city for detection of diabetes in-
sipidus. Copeptin has good, but not perfect dis-
criminatory capacity (2).
Copeptin and kidneys disease
Copeptin is associated with autosomal dominant 
polycystic kidney disease (ADPKD) as well. ADPKD 
is the most common hereditary kidney disease 
which is characterized by progressive cyst forma-
tion in both kidneys. AVP binds to V2 receptors in 
the distal tubules and collecting ducts promoting 
water absorption and production of cAMP. cAMP 
plays an important role in the stimulation of cyst 
growth in the kidney. Since copeptin refl ects AVP 
concentration, measurement of copeptin can pro-
vide valuable information about the severity of 
ADPKD. Higher copeptin concentration is associat-
ed with poor renal function, lower eff ective renal 
blood fl ow, larger kidneys and albuminuria. Co-
peptin is associated with plasma osmolarity, but 
not with 24-hour urine volume, 24-hour urine os-
molarity or fractional excretion of urea. In people 
with lower glomerular fi ltration, the fact that co-
peptin is partly cleared by the kidney probably 
isn’t an explanation for higher concentration of co-
peptin because increased copeptin concentration 
would induce a lowering of plasma osmolarity, 
which would lead to a decrease of copeptin (47).
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Copeptin, diabetes mellitus and metabolic 
syndrome
Activation of the hypothalamic-pituitary-adrenal 
axis by AVP in chronic psychosocial stress is one of 
the mediators associated with insulin resistance, 
diabetes mellitus, obesity and metabolic syn-
drome (16,48). AVP directly stimulates the secre-
tion of cortisol by activating V1a receptors, which 
interferes with insulin activity, stimulates glucagon 
secretion and glycogenolysis. This process subse-
quently leads to an increase in blood glucose. AVP 
also by activating the V1b receptors on the chro-
maffi  n cells in the adrenal medulla increases epi-
nephrine which also contributes to the develop-
ment of hyperglycemia through glycogenolysis in 
the liver (48). Raised AVP, as a result of resistance of 
AVP to V1a receptor, might also contribute to insu-
lin resistance and development of diabetes melli-
tus by stimulation of V1b receptor (16). Therefore, 
copeptin could be a new potential biomarker of 
insulin resistance and diabetes mellitus.
Copeptin is also associated with several compo-
nents of metabolic syndrome including obesity, 
dyslipidemia, elevated concentration of triglycer-
ides and low HDL-cholesterol. The association of 
copeptin with higher triglyceride concentration 
may be secondary to increased hepatic triglycer-
ide synthesis due to glucocorticoids, glucagon and 
epinephrine released under stress (all of which are 
regulated by AVP) (48). Enhörning et al. reported 
that elevated copeptin concentration at baseline 
predicted the incidence of diabetes mellitus and 
abdominal obesity during a long-term follow-up 
of 15.8 years on average. The association between 
copeptin at baseline and the incidence of diabetes 
mellitus is independent of the incidence of ab-
dominal obesity and vice versa, so it is possible that 
AVP independently triggers two diff erent path-
ways leading to diabetes mellitus and abdominal 
obesity. Despite this, there is the possibility that a 
primary elevation of AVP by increasing abdominal 
fat deposition leads to the development of diabe-
tes mellitus (49).
Copeptin and central nervous system diseases
In intracerebral hemorrhage (ICH) formation of 
edema in the brain indicates an unfavorable out-
come. It has been shown that blockade of AVP re-
ceptors reduces brain edema. This suggests that 
AVP has an important role in the formation of brain 
edema (17,50,51). Thus, measurement of copeptin 
can indicate existing or developing brain edema 
which can help in identifying patients with in-
creased risk of edema formation (50). Also, after 
ICH copeptin concentration in plasma is signifi -
cantly increased, refl ecting the severity of hemor-
rhagic damage and predicting long-term clinical 
outcome. Copeptin also helps to identify patients 
with risk of early neurological deterioration and 
correlates with hematoma volume, which is direct-
ly associated with clinical severity and outcome af-
ter ICH (50-52). Other biomarkers (D-dimer, gluta-
mate, matrix metalloproteinases and protein 
S100b) can also predict early neurological deterio-
ration and mortality in patients with ICH by way of 
diff erent pathophysiological processes. Therefore, 
it is advised that prognostic assessments and deci-
sions about management of ICH rely on few pa-
rameters where copeptin as a new prognostic bio-
marker is used in combination with other biomark-
ers (50). Copeptin, unlike the other brain biomark-
ers, is directly secreted into the systemic circula-
tion. This fact gives relevance to copeptin mea-
surement in ICH (17). In other conditions, such as 
ischemic stroke, aneurysmal subarachnoid hemor-
rhage and head injury, copeptin concentration is 
elevated as well (53). In this group of patients high 
copeptin concentration in peripheral blood is as-
sociated with mortality and poor neurologic out-
come (51). Yu et al. reported that copeptin increas-
es with severity of brain injury and therefore, its 
measurements after brain injury provides an op-
portunity to distinguish patients with a one-year 
good or poor outcome (17).
Conclusion
Copeptin, as a biomarker released into the circula-
tion under endogenous stress, could be a poten-
tially promising biomarker in diagnosis of various 
diseases and prediction of functional outcomes. 
Since it is not specifi c to a certain disease, copep-
tin could be used as an adjunct with more specifi c 
biomarkers where it may increase diagnostic accu-
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racy and aid clinicians in making better diagnostic 
judgements. However, copeptin is still in its infan-
cy and more research is needed in order to prove 
its clinical usefulness.
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